Administration of antibiotics and therapeutic agents

• US 10,099,045 B2
• Filed: 05/29/2015
• Issued: 10/16/2018
• Est. Priority Date: 09/12/2008
• Status: Active Grant

• Current Assignee: Sonescence, Inc.
• Original Assignee: Sonescence, Inc.
• Inventors: Silberg, Barry Neil
• Primary Examiner(s): Bosques, Edelmira
• Application Number:
  US14/725,694
• Publication Number:
  US 20150258320A1
• Time in Patent Office: 1,236 Days
• Field of Search: 604 22
• CPC Class Codes: A61B 17/3211 Surgical scalpels, knives; Accessories therefor
• CPC Class Codes: A61B 2017/00889 antimicrobial, disinfectant
• CPC Class Codes: A61K 31/546 containing further heterocyclic rings, e.g. cephalothin
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61M 37/0092 using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
• CPC Class Codes: A61N 2007/0004 Applications of ultrasound therapy
• CPC Class Codes: A61N 2007/0017 Wound healing
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

Antibiotics are administered in a surgical site subcutaneously via a small or stab incision in the surgical field. Transcutaneous ultrasonic vibrations are applied across the surgical field, which is then opened in the usual manner, to thereby provide a surgical field which contains a vastly higher and more effective level of antibiotic. At the same time the underlying tissue is hydrated.

Claims

1. A MRSA infection treatment system for treating a MRSA infected tissue of a patient, the MRSA infection treatment system comprising:

a solution comprising;

saline; and

a dose of Vancomycin dissolved in the saline, wherein the Vancomycin is not encapsulated in vesicles, wherein the dose of Vancomycin is sufficient for treatment of the MRSA infected tissue;

a blunt cannula configured for subcutaneous injection of the solution with the dose of Vancomycin dissolved in the saline into a treatment field associated with the MRSA infected tissue; and

an ultrasound system comprising;

a handle;

an ultrasonic transducer head operatively coupled with the handle, the ultrasonic transducer head comprising crystals embedded in a polymer, the handle configured to facilitate handling and positioning of the ultrasonic transducer head to contact a surface of a skin tissue; and

a power source operatively coupled with the ultrasonic transducer head, the power source and ultrasonic transducer head of the ultrasound system configured to broadcast ultrasound transcutaneously from the ultrasonic transducer head,

wherein the ultrasound system is configured to broadcast ultrasound transcutaneously from the ultrasonic transducer head at a power density of 2.5 to 4 W/cm² and at a frequency less than 5 MHz for less than 5 minutes toward the treatment field associated with the MRSA infected tissue that has been injected subcutaneously with the solution,

wherein the power source and ultrasonic transducer head of the ultrasound system are configured to broadcast ultrasound at the power density of 2.5 to 4 W/cm² and at the frequency less than 5 MHz for less than 5 minutes to interact with the subcutaneously injected solution to disperse the subcutaneously injected solution with the dose of Vancomycin dissolved therein through the treatment field and into the MRSA infected tissue via microstreaming or by cavitation; and

such that interaction of wherein the broadcasted ultrasound is configured to interact with the subcutaneously injected solution sufficiently disperses the dose of Vancomycin through the MRSA infected tissue at therapeutically effective concentrations for treating the MRSA infected tissue.

2. The MRSA infection treatment system of claim 1, further comprising a solution warmer for prewarming the solution prior to subcutaneous injection.

3. The MRSA infection treatment system of claim 1, wherein the broadcasted ultrasound is configured to interact with the solution to disperse the solution with the dose of Vancomycin dissolved therein down to a deep fascia tissue of the patient.

4. The MRSA infection treatment system of claim 1, further comprising a temperature monitor for monitoring a temperature of the treatment field during treatment of the MRSA infected tissue.

5. The system of claim 1, wherein the dose of Vancomycin is sufficient to achieve at least a minimum inhibitory concentration (MIC) within the treatment field associated with the MRSA infected tissue while remaining below serum concentration levels associated with toxic effects.

6. The system of claim 1, wherein the dose is a fraction of a corresponding standard intravenous dose of Vancomycin for the treatment field.

7. The system of claim 1, wherein the ultrasound system is configured to broadcast ultrasound transcutaneously from the ultrasonic transducer head at a frequency between 0.5 to 5 MHz to facilitate dispersal of the solution throughout the treatment field associated with the MRSA infected tissue in less than 5 minutes.